KR900009572A - 프로페논 옥심 에테르, 그의 제조방법 및 그를 함유하는 약학적 조성물 - Google Patents

프로페논 옥심 에테르, 그의 제조방법 및 그를 함유하는 약학적 조성물

Info

Publication number
KR900009572A
KR900009572A KR1019890017809A KR890017809A KR900009572A KR 900009572 A KR900009572 A KR 900009572A KR 1019890017809 A KR1019890017809 A KR 1019890017809A KR 890017809 A KR890017809 A KR 890017809A KR 900009572 A KR900009572 A KR 900009572A
Authority
KR
South Korea
Prior art keywords
preparation
pharmaceutical composition
composition containing
containing same
oxime ether
Prior art date
Application number
KR1019890017809A
Other languages
English (en)
Other versions
KR0156910B1 (ko
Inventor
꼬뉘 크리스띠앙
괼 빠뜨릭
라뵈외우 베르나르
리날디 뮈리에
Original Assignee
소시에떼 아노님 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소시에떼 아노님 사노피 filed Critical 소시에떼 아노님 사노피
Publication of KR900009572A publication Critical patent/KR900009572A/ko
Application granted granted Critical
Publication of KR0156910B1 publication Critical patent/KR0156910B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/15Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/50Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1019890017809A 1988-12-02 1989-12-02 프로페논 옥심 에테르, 그의 제조방법 및 그를 함유하는 약학적 조성물 KR0156910B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8815860A FR2639942B1 (fr) 1988-12-02 1988-12-02 Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
KR900009572A true KR900009572A (ko) 1990-07-04
KR0156910B1 KR0156910B1 (ko) 1998-12-01

Family

ID=9372544

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890017809A KR0156910B1 (ko) 1988-12-02 1989-12-02 프로페논 옥심 에테르, 그의 제조방법 및 그를 함유하는 약학적 조성물

Country Status (21)

Country Link
US (2) US5166416A (ko)
EP (1) EP0373998B1 (ko)
JP (1) JP2562503B2 (ko)
KR (1) KR0156910B1 (ko)
AR (1) AR245704A1 (ko)
AU (2) AU623706B2 (ko)
CA (1) CA2004350C (ko)
CZ (1) CZ419091A3 (ko)
DE (1) DE68908374T2 (ko)
DK (1) DK174434B1 (ko)
ES (1) ES2059804T3 (ko)
FI (1) FI94752C (ko)
FR (1) FR2639942B1 (ko)
HK (1) HK1001557A1 (ko)
HU (1) HU211463A9 (ko)
IE (1) IE63400B1 (ko)
IL (1) IL92519A (ko)
NO (1) NO171269C (ko)
NZ (2) NZ240166A (ko)
PT (1) PT92446B (ko)
ZA (1) ZA899201B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
IL103106A (en) * 1991-09-25 1998-06-15 Sanofi Elf Sites of tynocyclopentanone oximes, their preparation and pharmaceutical preparations containing them
HU213421B (en) * 1993-04-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar New basic ethers, pharmaceutical compns. containing the said compds. and process for prepg. them
US5844000A (en) * 1997-06-12 1998-12-01 Sanofi Propenone oxime ethers and pharmaceutical compositions containing them
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2787328A1 (fr) 1998-12-22 2000-06-23 Sanofi Sa Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures
CN1674901A (zh) * 2002-08-05 2005-09-28 桑多斯股份公司 新的地氯雷他定半富马酸盐及其多晶型物
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1701934B1 (en) * 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY
ES2359725T3 (es) 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US20090076159A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EP2266554A1 (en) 2009-05-26 2010-12-29 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
JP2012508792A (ja) * 2008-11-13 2012-04-12 サノフイ エプリバンセリンを使用して睡眠障害を治療する方法
EP2186511A1 (en) 2008-11-13 2010-05-19 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
FR2938534B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine
JPWO2010092771A1 (ja) * 2009-02-10 2012-08-16 日本曹達株式会社 含窒素化合物および有害生物防除剤
EP2255726A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2255807A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
EP2269600A1 (en) 2009-07-02 2011-01-05 Sanofi-Aventis Treatment of sleep disorders using eplivanserin in COPD patients
CN101941919B (zh) * 2009-07-07 2014-07-02 天津药物研究院 一种制备顺式肟及肟醚衍生物的方法
CN106883141B (zh) * 2017-03-15 2018-08-10 何黎琴 一种丹皮酚肟醚类化合物、其制备方法及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094374A (en) * 1963-11-21 1967-12-13 Gen Aniline & Film Corp Diazotype materials
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL7503311A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL7503312A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4279930A (en) * 1978-10-10 1981-07-21 The Upjohn Company Process for treating inflammation
AU532700B2 (en) * 1979-04-02 1983-10-13 Sumitomo Chemical Company, Limited Diphenylalkanoether
FI92189C (fi) * 1986-03-17 1994-10-10 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisen difenyylimetaanijohdannaisen valmistamiseksi
GB8617648D0 (en) * 1986-07-18 1986-08-28 Ici Plc Fungicides
KR0139296B1 (ko) * 1988-11-21 1998-05-15 가와무라 시게꾸니 칼콘 유도체 및 그 제조 방법
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
AU1218392A (en) 1992-05-28
DK605989D0 (da) 1989-11-30
KR0156910B1 (ko) 1998-12-01
PT92446A (pt) 1990-06-29
DE68908374D1 (de) 1993-09-16
AU4568889A (en) 1990-06-07
US5166416A (en) 1992-11-24
DK174434B1 (da) 2003-03-03
NO894786D0 (no) 1989-11-30
FI895757A0 (fi) 1989-12-01
NO171269B (no) 1992-11-09
PT92446B (pt) 1995-07-18
CZ419091A3 (en) 1993-05-12
FI94752B (fi) 1995-07-14
AR245704A1 (es) 1994-02-28
ES2059804T3 (es) 1994-11-16
NO894786L (no) 1990-06-05
JP2562503B2 (ja) 1996-12-11
CA2004350A1 (en) 1990-06-02
IE63400B1 (en) 1995-04-19
US5290951A (en) 1994-03-01
FI94752C (fi) 1995-10-25
IE893848L (en) 1990-06-02
HU211463A9 (en) 1995-11-28
JPH02262552A (ja) 1990-10-25
IL92519A (en) 1994-05-30
DK605989A (da) 1990-06-03
EP0373998B1 (fr) 1993-08-11
NO171269C (no) 1993-02-17
NZ240166A (en) 1992-02-25
NZ231606A (en) 1992-02-25
EP0373998A1 (fr) 1990-06-20
FR2639942A1 (fr) 1990-06-08
AU640310B2 (en) 1993-08-19
FR2639942B1 (fr) 1991-03-29
AU623706B2 (en) 1992-05-21
ZA899201B (en) 1990-09-26
CA2004350C (en) 1997-06-03
HK1001557A1 (en) 1998-06-26
DE68908374T2 (de) 1994-01-05

Similar Documents

Publication Publication Date Title
KR900009572A (ko) 프로페논 옥심 에테르, 그의 제조방법 및 그를 함유하는 약학적 조성물
DK165949C (da) 1,4-dihydropyridinderivater, fremgangsmaader til fremstilling deraf og farmaceutiske praeparater indeholdende forbindelserne
IL81790A0 (en) Hydroxylamine derivatives,their manufacture and pharmaceutical compositions containing them
IT1232149B (it) Composizione farmaceutica contenente ranitidina, e metodo per prepararla
FI901102A0 (fi) Farmaceutiska kompositioner.
FI922364A0 (fi) Farmaceutiska kompositioner.
DK163923C (da) 2-phenyl-3-aminomethyl-imidazooe1,2-aaapyridinderivater og farmaceutisk praeparat indeholdende saadanne forbindelser
IT8721411A0 (it) Composizione farmaceutica idrosolubile contenente n acetilsisteina.
DE3576117D1 (de) Mehrphasige pharmazeutische zusammensetzung.
IT8721410A0 (it) Composizione farmaceutica idrosolubile contenente n acetilcisteina.
FI872733A (fi) Farmaceutiska kompositioner.
KR880700814A (ko) 아미노글리코사이드 스테로이드, 이의 제조방법, 이의 용도 및 이를 함유하는 약제학적 조성물
DE3066434D1 (en) Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
FI872313A (fi) Farmaceutiska kompositioner.
KR880700815A (ko) 아미노글리코사이드 스테로이드, 그의 제조방법, 그의 용도 및 이를 함유하는 약제학적 조성물
IL91675A0 (en) Cyclic compounds,pharmaceutical compositions containing the same and processes for the preparation thereof
KR900009580A (ko) 벤젠 유도체, 그 제조방법 및 그를 함유하는 약학 조성물
KR900700452A (ko) 테트라히드로피리딘 유도체, 그를 함유하는 약학 조성물 및 그의 제조방법
IT8522773A0 (it) Composizione farmaceutica contenente fosfocreatina e metodo per preparla.
DK340388D0 (da) Aminocyklopentylaetere, fremstilling deraf og farmaceutisk praeparat indeholdende saadanne forbindelser
DK488385A (da) N6-bicycloadenosinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende saadanne forbindelser
DE3670635D1 (de) Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
PT84339A (pt) 1,6-naphthyridine derivatives process for the preparation thereof and pharmaceutical compositions containing them
DK0806949T3 (da) Ny farmaceutisk komposition, der indeholder trimebutin, og fremgangsmåde til fremstilling deraf
IL76327A (en) Phenylacetonitrile derivatives,process for the preparation thereof and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120628

Year of fee payment: 15

EXPY Expiration of term